Drugs / CBP-307
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05040113 | Sep → Oct 2021 | — | Connect Biopharm LLC | Completed | No outcome recorded |
| Phase 1 | NCT04818229 | Jun 2021 → Mar 2022 | autoimmune disease | Connect Biopharm LLC | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04700449 | Feb 2019 → Feb 2022 | ulcerative colitis | Connect Biopharm LLC | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT02280434 Comparator | Nov 2014 → Aug 2015 | autoimmune disease | Connect Biopharm LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CBP-307 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02280434 ↗ |
| Route | Oral | “CBP-307 following oral single and multiple escalating dose administration” NCT02280434 ↗ |